Before you sell to, join or invest in Immunovant, Inc.
MentionFox check on Immunovant, Inc.: only 1 source on file so far (checked 6 November 2026). Run a full check before you rely on it. mentionfox.com/c/funding/immunovant-inc-form-d-25000001
Check Immunovant, Inc. before you sell to, join or invest Free, no sign-up: every record on file, each linked to its source.
Immunovant, Inc. filed a Form D with the Securities and Exchange Commission on 2025-01-21.
Immunovant, Inc. filed a Form D notice of an exempt securities offering with the SEC on January 21, 2025. The filing reports $450M sold. Its industry group is Pharmaceuticals. It names Pete Salzmann (Executive Officer, Director), Eva Renee Barnett (Executive Officer), Michael Geffner (Executive Officer) (SEC Form D, January 21, 2025).
Is this your company?
125 companies raised this week.
Companies that just raised money, and the people to call. Before you unlock: the company, the amount, the date and what is inside (for example 2 people, phone, LinkedIn). After: the officers and directors the filing names with their roles, how to reach the company, and a person's email only when we found one.
| Andersen Aggregator LLC | $1.9B | Business services |
| AT Umbrella LLC | $1.9B | Business services |
| Legora, Inc. | $221M | AI and software |
| MD INVESTMENT LLC | $169M | Business services |
| Serval Inc. | $149M | AI and software |
Sell to companies like Immunovant, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-01-21 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Immunovant, Inc.
Free to see. No signup.
Get an email when Immunovant, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Immunovant, Inc. raises, hires or launches. No email unless you switch it on.
Watch Immunovant, Inc. →Get the full cited report on Immunovant, Inc.
What the filing shows about Immunovant, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Immunovant, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Immunovant, Inc.'s address as 320 West 37TH Street, New York, NY 10018.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Immunovant, Inc. is a registered filer with the SEC (CIK 1764013) and has filed since 2025-01-21. 1 filing is on record, the latest on 2025-01-21.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Immunovant, Inc.'s Form D of 2025-01-21 names Pete Salzmann, Eva Renee Barnett, Michael Geffner and 10 more as its officers, directors or promoters.
Its new offerings report $450M sold across 1 offering, as its own filings state.
Trailing twelve months. 155 filings in Pharmaceuticals, totalled by week.
Pete Salzmann is named as Executive Officer and Director on the Form D that Immunovant, Inc. filed with the SEC on 21 January 2025, one of 13 people that filing names.
Eva Renee Barnett is named as Executive Officer on the Form D that Immunovant, Inc. filed with the SEC on 21 January 2025, one of 13 people that filing names.
Michael Geffner is named as Executive Officer on the Form D that Immunovant, Inc. filed with the SEC on 21 January 2025, one of 13 people that filing names.
Melanie Gloria is named as Executive Officer on the Form D that Immunovant, Inc. filed with the SEC on 21 January 2025, one of 13 people that filing names.
Bill Macias is named as Executive Officer on the Form D that Immunovant, Inc. filed with the SEC on 21 January 2025, one of 13 people that filing names.
Jay Stout is named as Executive Officer on the Form D that Immunovant, Inc. filed with the SEC on 21 January 2025, one of 13 people that filing names.
Christopher Van Tuyl is named as Executive Officer on the Form D that Immunovant, Inc. filed with the SEC on 21 January 2025, one of 13 people that filing names.
Frank Torti is named as Director on the Form D that Immunovant, Inc. filed with the SEC on 21 January 2025, one of 13 people that filing names.
Andrew Fromkin is named as Director on the Form D that Immunovant, Inc. filed with the SEC on 21 January 2025, one of 13 people that filing names.
Douglas Hughes is named as Director on the Form D that Immunovant, Inc. filed with the SEC on 21 January 2025, one of 13 people that filing names.
George Migausky is named as Director on the Form D that Immunovant, Inc. filed with the SEC on 21 January 2025, one of 13 people that filing names.
Atul Pande is named as Director on the Form D that Immunovant, Inc. filed with the SEC on 21 January 2025, one of 13 people that filing names.
Eric Venker is named as Director on the Form D that Immunovant, Inc. filed with the SEC on 21 January 2025, one of 13 people that filing names.
13 people named on the filing — 7 holding an executive role and 6 as directors only.
Named as of the 2025-01-21 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
Of the 13 names on this filing, 12 are drawn here to keep the picture readable. The People tab lists them all.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Immunovant, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Immunovant, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Immunovant, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Immunovant, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Immunovant, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Immunovant, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Pharmaceuticals raises in New York
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/immunovant-inc-form-d-25000001